Skip to main content

Advertisement

SpringerLink
Log in

Does physician specialty affect persistence to pharmacotherapy among patients with overactive bladder syndrome?

  • Original Article
  • Published:
International Urogynecology Journal Aims and scope Submit manuscript

Abstract

Introduction and hypothesis

We compared persistence on overactive bladder (OAB) pharmacotherapy in patients treated in the Female Pelvic Medicine and Reconstructive Surgery (FPMRS) department compared with patients treated in the Internal Medicine (IM) and General Urology (GU) departments within an integrated health-care system. We hypothesized that persistence would be higher among FPMRS patients.

Methods

This was a retrospective cohort study. Patients with at least one prescription for OAB between January 2003 and July 2014 were identified. Demographic, prescription and treatment specialty data and data on the use of third-line therapies were collected. The primary outcome was persistence, defined as days on continuous pharmacotherapy. Discontinuation was defined as a treatment gap of ≥45 days. Discontinuation-free probabilities were calculated using the Kaplan-Meier method and compared among the specialties. Predictors of persistence were estimated using logistic regression with adjustment for covariates. Pearson correlation coefficients were calculated to identify risk associations.

Results

A total of 252 subjects were identified. At 12 weeks, 6 months and 1 year, FPMRS patients had the highest persistence rates of 93 %, 87 % and 79 % in contrast to 72 %, 68 % and 50 % in GU patients, and 83 %, 71 % and 63 % in IM patients (p = 0.006, p = 0.007, p = 0.001, respectively). The median persistence in FPMRS patients was 738 days, in GU patients 313 days and in IM patients 486 days (p = 0.006). Of the FPMRS patients, 61 % switched to at least a second medication, as compared to 27 % of IM patients and 14 % of GU patients (p < 0.0001).

Conclusions

Persistence on OAB pharmacotherapy was higher among FPMRS patients than among GU and IM patients in this community setting. These results suggest that persistence is higher under subspecialist supervision.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Basra RK, Wagg A, Chapple C, Cardozo L, Castro-Diaz D, Pons ME et al (2008) A review of adherence to drug therapy in patients with overactive bladder. BJU Int 102:774–779.

    Article  PubMed  Google Scholar 

  2. Stewart W, Rooyen JV, Cundiff F, Abrams P, Herzog AR, Corey R et al (2003) Prevalence and burden of overactive bladder in the United States. World J Urol 20:327–336.

    CAS  PubMed  Google Scholar 

  3. Coyne KS, Sexton CC, Vats V, Thompson C, Kopp ZS, Milsom I (2011) National community prevalence of overactive bladder in the United States stratified by sex and age. Urology 77(5):1081–1087.

    Article  PubMed  Google Scholar 

  4. Irwin DE, Milsom I, Hunskaar S, Reilly K, Kopp Z, Herschorn S et al (2006) Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 50:1306–1315.

    Article  PubMed  Google Scholar 

  5. Cheung WW, Khan NH, Choi KK, Bluth MH, Vincent MT (2009) Prevalence, evaluation and management of overactive bladder in primary care. BMC Fam Pract 10:8.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Cheung WW, Borawski D, Abulafia O, Vincent MT, Harel M, Bluth MH (2011) Characterization of overactive bladder in women in a primary car setting. Open Access J Urol 3:29–34.

    PubMed  PubMed Central  Google Scholar 

  7. Staskin DR, MacDiarmid SA (2006) Pharmacologic management of overactive bladder: practical options for the primary care physician. Am J Med 119(3 Suppl 1):24–8.

    Article  PubMed  Google Scholar 

  8. Siu JY (2015) Communicating with mismatch and tension: treatment provision experiences of primary care doctors treating patients with overactive bladder in Hong Kong. BMC Fam Pract 16:160.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Jirschele K, Ross R, Goldberg G, Botros S (2015) Physician attitudes toward urinary incontinence identification. Female Pelvic Med Reconstr Surg 21(5):273–276.

    Article  PubMed  Google Scholar 

  10. Finkelstein K, Glosner S, Sanchez RJ, Uddin N (2008) Prevalence of probable overactive bladder in private obstetrics and gynecology group practice. Curr Med Res Opin 24(4):1083–1090.

    Article  PubMed  Google Scholar 

  11. Nguyen K, Hunter K, Wagg A (2013) Knowledge and understanding of urinary incontinence: survey of family practitioners in northern Alberta. Can Fam Physician 59:e330–e337.

    PubMed  PubMed Central  Google Scholar 

  12. Rosenberg M, Witt ES, Barkin J, Miner M (2014) A practical primary care approach to overactive bladder. Can J Urol 31 Suppl 2:2–11.

    Google Scholar 

  13. Gormley EA, Lightner DJ, Burgio KL, Chai TC, Clemens JQ, Culkin DJ et al (2012) Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline. J Urol 188(6 Suppl):2455–2463.

    Article  PubMed  Google Scholar 

  14. Kalder M, Pantazis K, Dinas K, Albert US, Heilmaier C, Kostev K (2014) Discontinuation and treatment using anticholinergic medications in patients with urinary incontinence. Obstet Gynecol 124:794–800.

    Article  CAS  PubMed  Google Scholar 

  15. Malinar AS, Rejas J, Navarro-Artieda R, Aguado-Jodar A, Ruiz-Torrejon A, Ibanez-Nolla J et al (2014) Antimuscarinic persistence patterns in newly treated patients with overactive bladder: a retrospective comparative analysis. Int Urogynecol J 25:485–492.

    Article  Google Scholar 

  16. Kobelt G (1997) Economic considerations and outcome measurement in urge incontinence. Urology 50(6A Suppl):100–107.

    Article  CAS  PubMed  Google Scholar 

  17. Wagg A, Compion G, Fahey A, Siddiquui E (2012) Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience. BJU Int 110:1767–1774.

    Article  CAS  PubMed  Google Scholar 

  18. Sexton CC, Notte S, Maroulis C, Dmochowski RR, Cardozo L, Subramanian D et al (2011) Persistence and adherence in the treatment of overactive bladder syndrome with anticholinergic therapy: a systemic review of the literature. Int J Clin Pract 65:567–585.

    Article  CAS  PubMed  Google Scholar 

  19. Chancellor MB, Migliaccio-Walle K, Bramley T, Chaudhari SL, Corbell C, Globe D (2013) Long-term patterns of use and treatment failure with anticholinergic agents for overactive bladder. Clin Ther 25:1744–1751.

    Article  Google Scholar 

  20. Shaya FT, Blume S, Gu A, Zyczynski T, Jumadilova Z (2005) Persistence with overactive bladder pharmacotherapy in a Medicaid population. Am J Manag Care 11:S121–S129.

    PubMed  Google Scholar 

  21. Yu TF, Nichol MB, Yu AP, Ahn J (2005) Persistence and adherence of medication for chronic overactive bladder/urinary incontinence in the California Medicaid program. Value Health 8:495–504.

    Article  PubMed  Google Scholar 

  22. Echols K, Verma U, Policaro F, Medina CA (2000) Idiopathic hyperactivity and ditropan: an efficacy and compliance issue. Obstet Gynecol 95(4 Suppl 1):S24.

    Article  Google Scholar 

  23. Kelleher CJ, Cardozo LD, Khullar V, Salvatore S (1997) A medium-term analysis of the subjective efficacy of treatment of women with detrusor instability and low bladder compliance. Br J Obstet Gynaecol 104:988–993.

    Article  CAS  PubMed  Google Scholar 

  24. Visco AG, Brubaker L, Jelovsek E, Wilson TS, Norton P, Zyczynski HM et al (2016) Adherence to oral therapy for urgency urinary incontinence: results from the Anticholinergic versus Botox Comparison (ABC) trial. Female Pelvic Med Reconstr Surg 22:24–28.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Equator network: Enhancing the QUality and Transparency Of Health Research (2016) The STOBE guidelines. http://www.equator-network.org. Accessed 7 August 2016.

  26. Johnston BJ (2013) The role of patient experience and its influence on adherence to anti-depressant treatment. J Psychosoc Nurs Ment Health Serv 51(12):29–37.

    Article  PubMed  Google Scholar 

  27. Smith AL, Nissim HA, Le TX, Khan A, Maliski SL, Litwin MS et al (2011) Misconceptions and miscommunication among aging women with overactive bladder symptoms. Urology 77(1):55–59.

    Article  PubMed  Google Scholar 

  28. Grimes D (2010) Epidemiologic research using administrative databases. Obstet Gynecol 116:1018–1019.

    Article  PubMed  Google Scholar 

  29. Yeaw J, Benner JS, Walt JG, Siams S, Smith DB (2009) Comparing adherence and persistence across 6 chronic medication classes. J Manag Care Pharm 15:728–740.

    PubMed  Google Scholar 

  30. World Health Organization (2003) Adherence to long-term therapies: evidence for action. World Health Organization, Geneva. http://www.who.int/chp/knowledge/publications/adherence_report/en/index.html. Accessed 7 August 2016.

Download references

Author information

Authors and Affiliations

  1. Department of Obstetrics and Gynecology, Division of Female Pelvic Medicine and Reconstructive Surgery, University of Chicago, NorthShore University HealthSystem, Center for Pelvic Health, 9650 Gross Point Road, Suite 3900, Skokie, IL, 60076, USA

    Alexis M. Tran, Peter K. Sand, Miriam J. Seitz, Adam Gafni-Kane & Sylvia M. Botros

  2. Center for Biomedical and Research Informatics, NorthShore University Health System, Evanston, IL, USA

    Ying Zhou

Authors
  1. Alexis M. Tran
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Peter K. Sand
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Miriam J. Seitz
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Adam Gafni-Kane
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ying Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Sylvia M. Botros
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alexis M. Tran.

Ethics declarations

Conflicts of interest

None.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tran, A.M., Sand, P.K., Seitz, M.J. et al. Does physician specialty affect persistence to pharmacotherapy among patients with overactive bladder syndrome?. Int Urogynecol J 28, 409–415 (2017). https://doi.org/10.1007/s00192-016-3118-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00192-016-3118-1

Keywords

Search

Navigation